基本信息
views: 125
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Academic activities
He has supervised 8 PhD students (plus 5 ongoing), 10 Master students (plus 2
ongoing) and 8 diploma students (plus 1 ongoing)(details at Dissertations and theses).
He participated in several post graduate master courses in Greece; currently:
Molecular Biomedicine and Clinical Biochemistry and Molecular Diagnostics.
He has been invited to present his work to a plethora of scientific conferences (A nonexhaustive list can be found at Presentations).
He has served as a reviewer in >38 scientific journals (IF 3.51 -16.42), as well as in
the Faculty of F1000.
He has served as a reviewer/evaluator/rapporteur of national and international grant
proposals: ΓΓΕΤ, ΙΚΥ, ΕΛΙΔΕΚ, Alliance National de la Research (ANR), British
Lung Foundation, German-Israeli Foundation, Netherland Organization for Scientific
Research (NWO), Cyprus RIF, RIKEN/FANTOM, Welcome Trust, European
commission/Marie Curie.
In 2018, he received the National Academy of Athens research award for his work
on the role of ATX in liver fibrosis and cancer.
His lab is recognized as an “excellent” host center for respiratory research (RESPIRE4)
Other activities
He pioneered (2000-2007) the use of DNA microarrays and related bioinformatic tools
and set up the first expression profiling service unit in Greece offering services to
Fleming and external researchers.
He is a co-founder of Biomedcode Hellas, a Fleming spin-off for preclinical evaluation
studies and novel drug development and he has applied for eight patents (6 active).
He is a founding member of the Scientific Society for Rare Diseases & Orphan Drugs
(SSRDOD).
He supervised (2005-2011) the creation of several mouse databases, in the context of
various international collaborations aiming to promote mouse database functionalities
and interoperability.
He setup the Respiratory Unit of BSRC Fleming and various animal models of lung
diseases, allowing the investigation of pathogenetic genes and therapeutic
interventions.
He setup two biobanks with idiopathic pulmonary fibrosis (IPF) and lung cancer
patient samples (sera, plasma, BALF, tissue), promoting translational research.
He set up at the local MS facilities lipidomics, the quantification of more than 70
(lyso)phospholipids in biologic fluids and tissues.
He has signed >42 material transfer agreements for proprietary materials (genetically
modified mice and monoclonal antibodies)
He established a drug discovery pipeline for the identification of novel ATX
inhibitors, that can be applied for the pharmacological targeting of other novel drug
targets.
His work provided the scientific proof of principle for the ongoing clinical trials on
ATX inhibition in IPF patients.
He has supervised 8 PhD students (plus 5 ongoing), 10 Master students (plus 2
ongoing) and 8 diploma students (plus 1 ongoing)(details at Dissertations and theses).
He participated in several post graduate master courses in Greece; currently:
Molecular Biomedicine and Clinical Biochemistry and Molecular Diagnostics.
He has been invited to present his work to a plethora of scientific conferences (A nonexhaustive list can be found at Presentations).
He has served as a reviewer in >38 scientific journals (IF 3.51 -16.42), as well as in
the Faculty of F1000.
He has served as a reviewer/evaluator/rapporteur of national and international grant
proposals: ΓΓΕΤ, ΙΚΥ, ΕΛΙΔΕΚ, Alliance National de la Research (ANR), British
Lung Foundation, German-Israeli Foundation, Netherland Organization for Scientific
Research (NWO), Cyprus RIF, RIKEN/FANTOM, Welcome Trust, European
commission/Marie Curie.
In 2018, he received the National Academy of Athens research award for his work
on the role of ATX in liver fibrosis and cancer.
His lab is recognized as an “excellent” host center for respiratory research (RESPIRE4)
Other activities
He pioneered (2000-2007) the use of DNA microarrays and related bioinformatic tools
and set up the first expression profiling service unit in Greece offering services to
Fleming and external researchers.
He is a co-founder of Biomedcode Hellas, a Fleming spin-off for preclinical evaluation
studies and novel drug development and he has applied for eight patents (6 active).
He is a founding member of the Scientific Society for Rare Diseases & Orphan Drugs
(SSRDOD).
He supervised (2005-2011) the creation of several mouse databases, in the context of
various international collaborations aiming to promote mouse database functionalities
and interoperability.
He setup the Respiratory Unit of BSRC Fleming and various animal models of lung
diseases, allowing the investigation of pathogenetic genes and therapeutic
interventions.
He setup two biobanks with idiopathic pulmonary fibrosis (IPF) and lung cancer
patient samples (sera, plasma, BALF, tissue), promoting translational research.
He set up at the local MS facilities lipidomics, the quantification of more than 70
(lyso)phospholipids in biologic fluids and tissues.
He has signed >42 material transfer agreements for proprietary materials (genetically
modified mice and monoclonal antibodies)
He established a drug discovery pipeline for the identification of novel ATX
inhibitors, that can be applied for the pharmacological targeting of other novel drug
targets.
His work provided the scientific proof of principle for the ongoing clinical trials on
ATX inhibition in IPF patients.
Research Interests
Papers共 179 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2024): 129690-129690
Frontiers in medicine (2023): 1195501
International Journal of Molecular Sciencesno. 21 (2023): 15833-15833
Respiratory researchno. 1 (2023): 1-13
JOURNAL OF MEDICINAL CHEMISTRYno. 20 (2023): 14357-14376
Cellsno. 3 (2023): 511-511
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESno. 9 (2023): 8325-8325
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn